Logo image of RMTI

ROCKWELL MEDICAL INC (RMTI) Stock Fundamental Analysis

NASDAQ:RMTI - Nasdaq - US7743743004 - Common Stock - Currency: USD

0.97  -0.02 (-2.25%)

Fundamental Rating

4

Overall RMTI gets a fundamental rating of 4 out of 10. We evaluated RMTI against 188 industry peers in the Health Care Equipment & Supplies industry. The financial health of RMTI is average, but there are quite some concerns on its profitability. RMTI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

RMTI had negative earnings in the past year.
In the past year RMTI had a positive cash flow from operations.
In the past 5 years RMTI always reported negative net income.
In the past 5 years RMTI reported 4 times negative operating cash flow.
RMTI Yearly Net Income VS EBIT VS OCF VS FCFRMTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -0.49%, RMTI is in the better half of the industry, outperforming 72.34% of the companies in the same industry.
RMTI's Return On Equity of -0.84% is fine compared to the rest of the industry. RMTI outperforms 72.87% of its industry peers.
With a decent Return On Invested Capital value of 1.06%, RMTI is doing good in the industry, outperforming 67.55% of the companies in the same industry.
Industry RankSector Rank
ROA -0.49%
ROE -0.84%
ROIC 1.06%
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
RMTI Yearly ROA, ROE, ROICRMTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Operating Margin, with a value of 0.59%, RMTI is in the better half of the industry, outperforming 65.43% of the companies in the same industry.
The Gross Margin of RMTI (17.87%) is worse than 80.85% of its industry peers.
RMTI's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.59%
PM (TTM) N/A
GM 17.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
RMTI Yearly Profit, Operating, Gross MarginsRMTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RMTI is destroying value.
Compared to 1 year ago, RMTI has more shares outstanding
Compared to 5 years ago, RMTI has more shares outstanding
RMTI has a better debt/assets ratio than last year.
RMTI Yearly Shares OutstandingRMTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
RMTI Yearly Total Debt VS Total AssetsRMTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -7.12, we must say that RMTI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RMTI (-7.12) is worse than 74.47% of its industry peers.
The Debt to FCF ratio of RMTI is 4.63, which is a neutral value as it means it would take RMTI, 4.63 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of RMTI (4.63) is better than 82.98% of its industry peers.
RMTI has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.30, RMTI perfoms like the industry average, outperforming 47.34% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 4.63
Altman-Z -7.12
ROIC/WACC0.13
WACC8.42%
RMTI Yearly LT Debt VS Equity VS FCFRMTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RMTI has a Current Ratio of 2.95. This indicates that RMTI is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.95, RMTI perfoms like the industry average, outperforming 55.85% of the companies in the same industry.
A Quick Ratio of 2.50 indicates that RMTI has no problem at all paying its short term obligations.
RMTI's Quick ratio of 2.50 is in line compared to the rest of the industry. RMTI outperforms 56.38% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.5
RMTI Yearly Current Assets VS Current LiabilitesRMTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

RMTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.72%, which is quite impressive.
Looking at the last year, RMTI shows a quite strong growth in Revenue. The Revenue has grown by 12.82% in the last year.
The Revenue has been growing by 10.61% on average over the past years. This is quite good.
EPS 1Y (TTM)99.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)12.82%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-16.59%

3.2 Future

Based on estimates for the next years, RMTI will show a very negative growth in Earnings Per Share. The EPS will decrease by -156.07% on average per year.
RMTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.83% yearly.
EPS Next Y-701.43%
EPS Next 2Y-156.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-32.1%
Revenue Next 2Y-13.12%
Revenue Next 3Y13.83%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RMTI Yearly Revenue VS EstimatesRMTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
RMTI Yearly EPS VS EstimatesRMTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -2 -4 -6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

RMTI is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RMTI Price Earnings VS Forward Price EarningsRMTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, RMTI is valued cheaper than 96.28% of the companies in the same industry.
RMTI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RMTI is cheaper than 90.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.34
EV/EBITDA 7.49
RMTI Per share dataRMTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

A cheap valuation may be justified as RMTI's earnings are expected to decrease with -156.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-156.07%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RMTI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKWELL MEDICAL INC

NASDAQ:RMTI (6/12/2025, 8:27:56 PM)

0.97

-0.02 (-2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners25.7%
Inst Owner Change-14.28%
Ins Owners2.06%
Ins Owner Change7.88%
Market Cap33.14M
Analysts82.5
Price Target4.08 (320.62%)
Short Float %0.66%
Short Ratio0.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-88.24%
Min EPS beat(2)-198.04%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)84.73%
Min EPS beat(4)-198.04%
Max EPS beat(4)390.2%
EPS beat(8)5
Avg EPS beat(8)38.68%
EPS beat(12)9
Avg EPS beat(12)37.59%
EPS beat(16)11
Avg EPS beat(16)34.01%
Revenue beat(2)2
Avg Revenue beat(2)4.22%
Min Revenue beat(2)2.23%
Max Revenue beat(2)6.2%
Revenue beat(4)4
Avg Revenue beat(4)5.92%
Min Revenue beat(4)2.23%
Max Revenue beat(4)10.49%
Revenue beat(8)6
Avg Revenue beat(8)2.74%
Revenue beat(12)9
Avg Revenue beat(12)3.54%
Revenue beat(16)9
Avg Revenue beat(16)-1.29%
PT rev (1m)0%
PT rev (3m)-38.46%
EPS NQ rev (1m)-25%
EPS NQ rev (3m)-233.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-200%
Revenue NQ rev (1m)-2.62%
Revenue NQ rev (3m)-20.66%
Revenue NY rev (1m)1.2%
Revenue NY rev (3m)-17.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF 15.34
P/OCF 10.71
P/B 1.05
P/tB 1.61
EV/EBITDA 7.49
EPS(TTM)0
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)0.06
FCFY6.52%
OCF(TTM)0.09
OCFY9.34%
SpS2.86
BVpS0.92
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.49%
ROE -0.84%
ROCE 1.34%
ROIC 1.06%
ROICexc 1.77%
ROICexgc 3.12%
OM 0.59%
PM (TTM) N/A
GM 17.87%
FCFM 2.21%
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
F-Score7
Asset Turnover1.81
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 4.63
Debt/EBITDA 3.42
Cap/Depr 43.01%
Cap/Sales 0.96%
Interest Coverage 0.71
Cash Conversion 112.71%
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.5
Altman-Z -7.12
F-Score7
WACC8.42%
ROIC/WACC0.13
Cap/Depr(3y)323.45%
Cap/Depr(5y)234.89%
Cap/Sales(3y)5.5%
Cap/Sales(5y)3.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-701.43%
EPS Next 2Y-156.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.82%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-16.59%
Revenue Next Year-32.1%
Revenue Next 2Y-13.12%
Revenue Next 3Y13.83%
Revenue Next 5YN/A
EBIT growth 1Y108.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-246.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y118.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.96%
OCF growth 3YN/A
OCF growth 5YN/A